Literature DB >> 9212106

Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury.

C Indolfi1, E V Avvedimento, E Di Lorenzo, G Esposito, A Rapacciuolo, P Giuliano, D Grieco, L Cavuto, A M Stingone, I Ciullo, G Condorelli, M Chiariello.   

Abstract

Injury of the arterial wall induces the formation of the neointima. This structure is generated by the growth of mitogenically activated smooth muscle cells of the arterial wall. The molecular mechanism underlying the formation of the neointima involves deregulated cell growth, primarily triggered by the injury of the arterial wall. The activated gene products transmitting the injury-induced mitogenic stimuli have been identified and inhibited by several means: transdominant negative expression vectors, antisense oligodeoxynucleotides, adenovirus-mediated gene transfer, antibodies and inactivating drugs. Results of our study show that local administration of 3',5'-cyclic AMP and phosphodiesterase-inhibitor drugs (aminophylline and amrinone) to rats markedly inhibits neointima formation after balloon injury in vivo and in smooth muscle cells in vitro. The growth inhibitory effect of aminophylline was completely reversed by the inhibition of cAMP-dependent protein kinase A (PKA). These findings indicate an alternative approach to the treatment of diseases associated with injury-induced cell growth of the arterial wall, as stimulation of cAMP signaling is pharmacologically feasible in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212106     DOI: 10.1038/nm0797-775

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  53 in total

1.  Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options.

Authors:  Hakon Hakonarson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

2.  Sphingosine-1-phosphate receptor 3 promotes neointimal hyperplasia in mouse iliac-femoral arteries.

Authors:  Takuya Shimizu; Allison De Wispelaere; Martin Winkler; Travis D'Souza; Jacob Caylor; Lihua Chen; Frank Dastvan; Jessie Deou; Aesim Cho; Axel Larena-Avellaneda; Michael Reidy; Guenter Daum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-02       Impact factor: 8.311

Review 3.  Current understanding of coronary in-stent restenosis. Pathophysiology, clinical presentation, diagnostic work-up, and management.

Authors:  T M Schiele
Journal:  Z Kardiol       Date:  2005-11

Review 4.  Bare-metal stents versus drug-eluting stents for primary angioplasty: long-term outcome.

Authors:  Emilio Di Lorenzo; Giannignazio Carbone; Luigi Sauro; Alfredo Casafina; Michele Capasso; Rosario Sauro
Journal:  Curr Cardiol Rep       Date:  2011-10       Impact factor: 2.931

Review 5.  G-protein-mediated signaling in vascular smooth muscle cells - implications for vascular disease.

Authors:  Till F Althoff; Stefan Offermanns
Journal:  J Mol Med (Berl)       Date:  2015-06-14       Impact factor: 4.599

Review 6.  A2 adenosine receptors and vascular pathologies.

Authors:  Hillary A Johnston-Cox; Milka Koupenova; Katya Ravid
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

7.  Expression of Q227L-Galpha(s) inhibits intimal vessel wall hyperplasia after balloon injury.

Authors:  W Holness; T A Santore; G P Brown; J T Fallon; M B Taubman; R Iyengar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

8.  Pharmacologic agents elevating cAMP prevent arginase II expression and proliferation of pulmonary artery smooth muscle cells.

Authors:  Bernadette Chen; Andrea E Calvert; Xiaomei Meng; Leif D Nelin
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-23       Impact factor: 6.914

9.  Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice.

Authors:  Yannis Hara; Yassine Sassi; Christelle Guibert; Natacha Gambaryan; Peter Dorfmüller; Saadia Eddahibi; Anne-Marie Lompré; Marc Humbert; Jean-Sébastien Hulot
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

10.  Mice lacking the Cβ subunit of PKA are resistant to angiotensin II-induced cardiac hypertrophy and dysfunction.

Authors:  Linda C Enns; Kenneth L Bible; Mary J Emond; Warren C Ladiges
Journal:  BMC Res Notes       Date:  2010-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.